CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of ovarian cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with ovarian cancer.
  
  LEARNING OBJECTIVES

  • Understand the importance of genetic testing for women with newly diagnosed ovarian cancer (OC), and counsel patients regarding the clinical relevance of related testing results.
  • Appreciate published research findings with the use of PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and use this information to explain personalized treatment recommendations to patients.
  • Evaluate available clinical trial results with and approved indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC.
  • Recognize the rationale for targeting folate receptor alpha in OC, and consider emerging research findings with and the potential role of novel agents attempting to exploit this biomarker for patients with advanced disease.
  • Assess the toxicities associated with PARP inhibitors and other novel agents used for OC, and offer patients supportive management strategies to minimize and ameliorate these side effects.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for patients with OC, and counsel appropriate individuals about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Video Program: This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jennifer Filipi, MSN, NP
  Department of Gynecologic Oncology
  Massachusetts General Hospital Cancer Center
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  Kathleen N Moore, MD, MS
  Virginia Kerley Cade Chair in Developmental Therapeutics
  Associate Director for Clinical Research
  Director, Early Phase Drug Development
  Stephenson Cancer Center at the University of Oklahoma HSC
  Professor, Section of Gynecologic Oncology
  Associate Program Director, Gynecologic Oncology Fellowship
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma
  
  Advisory Committee: Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, I-Mab Biopharma, ImmunoGen Inc, IMXmed, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: Lilly, Merck, PTC Therapeutics; Data and Safety Monitoring Board/Committee: SQZ Biotech.
  
  Krishnansu S Tewari, MD
  Professor and Division Director
  Division of Gynecologic Oncology
  University of California, Irvine
  Irvine, California
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Regeneron Pharmaceuticals Inc, Tesaro, A GSK Company; Contracted Research (to Institution): AbbVie Inc, Clovis Oncology, Genentech, a member of the Roche Group, Merck, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck.
  
  Deborah Wright, MSN, APRN, AGCNS-BC
  Clinical Nurse Specialist
  TSET Phase I Program
  Lead Advanced Practice Provider
  Clinical Trials Office
  Stephenson Cancer Center
  University of Oklahoma Health Sciences Center
  Oklahoma City, Oklahoma
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, and Novocure Inc.
  
  Release date: May 2022
  Expiration date: May 2023
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.